Teva, Sandoz Launch At-Risk Versions of Pfizer Drug

Law360, New York (November 29, 2005, 12:00 AM EST) -- The U.S. Food and Drug Administration has given the green light to three generic drug makers’ plans to market their own versions of Pfizer’s Zithromax antibiotic. Two of the companies have decided to launch at risk versions of the drugs, in an effort to grab lucrative market share.

Israeli generics company Teva Pharmaceuticals, Novartis subsidiary Sandoz and Croatian drug maker Pilva have all received approval for 250, 500, and 600 mg doses of the drug, which generated $1.62 billion for Pfizer this year.

Teva and Sandoz...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.